Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for slowing lung scarring

NCT ID NCT03865927

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study tested an experimental drug called GKT137831 in 58 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing difficult. The drug aims to reduce lung damage caused by harmful molecules called reactive oxygen species. Researchers measured changes in blood markers of stress and collagen breakdown to see if the drug could slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Temple University Medical Center

    Philadelphia, Pennsylvania, 19140, United States

  • Tulane University Medical Center

    New Orleans, Louisiana, 70112, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Michigan Medical Center

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.